Case number 1:24-cv-01331
Amicus Therapeutics US, LLC et al v. Aurobindo Pharma Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jan 8, 2025 | 11 | ORDER in case 1:22-cv-01461-CJB; granting (10) Motion to Consolidate Cases in case 1:24-cv-01331-CFC. Signed by Judge Colm F. Connolly on 1/8/2025. Associated Cases: 1:24-cv-01331-CFC, 1:22-cv-01461-CJB (mws) (Entered: 01/08/2025) (2) |
| Jan 8, 2025 | N/A | Remark: Case associated with lead case: Create association to 1:22-cv-01461-CJB. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 22-1461-CJB ONLY. (mws) Modified on 1/31/2025 (mws). (Entered: 01/08/2025) (0) |
| Jan 7, 2025 | 10 | Joint MOTION to Consolidate Cases - Case No. 24-cv-1331-CFC into Lead Case No. 22-cv-1461-CJB - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Attachments: # 1 Text of Proposed Order)(Stover, Chad) (Entered: 01/07/2025) (0) |
| Dec 17, 2024 | 9 | STIPULATION TO EXTEND TIME for Defendants to Respond to the Complaint to February 6, 2025 - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) (Entered: 12/17/2024) (2) |
| Dec 17, 2024 | N/A | SO ORDERED, re 9 STIPULATION TO EXTEND TIME for Defendants to Respond to the Complaint to February 6, 2025, filed by Amicus Therapeutics, Inc., Amicus Therapeutics US, LLC. Reset Answer Deadlines: Aurobindo Pharma Ltd. answer due 2/6/2025; Aurobindo Pharma USA, Inc. answer due 2/6/2025. Ordered by Judge Colm F. Connolly on 12/17/2024. (kmd) (Entered: 12/17/2024) (0) |
| Dec 11, 2024 | N/A | Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) (Entered: 12/11/2024) (0) |
| Dec 11, 2024 | 8 | STANDING ORDER REGARDING BRIEFING IN ALL CASES. (mws) (Entered: 12/11/2024) (2) |
| Dec 6, 2024 | 1 | Complaint* (1) |
| Dec 6, 2024 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) (Entered: 12/09/2024) (3) |
| Dec 6, 2024 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: N/A. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 2/10/2026. (mpb) (Entered: 12/09/2024) (3) |
| Dec 6, 2024 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 12,042,489; 12,042,490; 12,109,205. (mpb) (Entered: 12/09/2024) (1) |
| Dec 6, 2024 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Amicus Therapeutics, Inc. for Amicus Therapeutics US, LLC filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc. (mpb) (Entered: 12/09/2024) (3) |
| Dec 6, 2024 | 6 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc. (mpb) (Entered: 12/09/2024) (3) |
| Dec 6, 2024 | 7 | Summons Issued as to Aurobindo Pharma Ltd. on 12/6/2024; Aurobindo Pharma USA, Inc. on 12/6/2024. (Attachments: # 1 Summons Issued)(mpb) (Entered: 12/09/2024) (0) |
